Cargando…

Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism

Empagliflozin is a newly developed antidiabetic drug to reduce hyperglycaemia by highly selective inhibition of sodium–glucose co-transporter 2. Hyperglycaemia is commonly seen in patients after cardiac arrest (CA) and is associated with worse outcomes. In this study, we examined the effects of empa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Yunke, Yu, Kai, Liang, Lian, Liu, Yuanshan, Song, Fengqing, Ge, Qiulin, Fang, Xiangshao, Yu, Tao, Huang, Zitong, Jiang, Longyuan, Wang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546214/
https://www.ncbi.nlm.nih.gov/pubmed/34712142
http://dx.doi.org/10.3389/fphar.2021.758080
_version_ 1784590146722594816
author Tan, Yunke
Yu, Kai
Liang, Lian
Liu, Yuanshan
Song, Fengqing
Ge, Qiulin
Fang, Xiangshao
Yu, Tao
Huang, Zitong
Jiang, Longyuan
Wang, Peng
author_facet Tan, Yunke
Yu, Kai
Liang, Lian
Liu, Yuanshan
Song, Fengqing
Ge, Qiulin
Fang, Xiangshao
Yu, Tao
Huang, Zitong
Jiang, Longyuan
Wang, Peng
author_sort Tan, Yunke
collection PubMed
description Empagliflozin is a newly developed antidiabetic drug to reduce hyperglycaemia by highly selective inhibition of sodium–glucose co-transporter 2. Hyperglycaemia is commonly seen in patients after cardiac arrest (CA) and is associated with worse outcomes. In this study, we examined the effects of empagliflozin on cardiac function in rats with myocardial dysfunction after CA. Non-diabetic male Sprague–Dawley rats underwent ventricular fibrillation to induce CA, or sham surgery. Rats received 10 mg/kg of empagliflozin or vehicle at 10 min after return of spontaneous circulation by intraperitoneal injection. Cardiac function was assessed by echocardiography, histological analysis, molecular markers of myocardial injury, oxidative stress, mitochondrial ultrastructural integrity and metabolism. We found that empagliflozin did not influence heart rate and blood pressure, but left ventricular function and survival time were significantly higher in the empagliflozin treated group compared to the group treated with vehicle. Empagliflozin also reduced myocardial fibrosis, serum cardiac troponin I levels and myocardial oxidative stress after CA. Moreover, empagliflozin maintained the structural integrity of myocardial mitochondria and increased mitochondrial activity after CA. In addition, empagliflozin increased circulating and myocardial ketone levels as well as heart β-hydroxy butyrate dehydrogenase 1 protein expression. Together, these metabolic changes were associated with an increase in cardiac energy metabolism. Therefore, empagliflozin favorably affected cardiac function in non-diabetic rats with acute myocardial dysfunction after CA, associated with reducing glucose levels and increasing ketone body oxidized metabolism. Our data suggest that empagliflozin might benefit patients with myocardial dysfunction after CA.
format Online
Article
Text
id pubmed-8546214
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85462142021-10-27 Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism Tan, Yunke Yu, Kai Liang, Lian Liu, Yuanshan Song, Fengqing Ge, Qiulin Fang, Xiangshao Yu, Tao Huang, Zitong Jiang, Longyuan Wang, Peng Front Pharmacol Pharmacology Empagliflozin is a newly developed antidiabetic drug to reduce hyperglycaemia by highly selective inhibition of sodium–glucose co-transporter 2. Hyperglycaemia is commonly seen in patients after cardiac arrest (CA) and is associated with worse outcomes. In this study, we examined the effects of empagliflozin on cardiac function in rats with myocardial dysfunction after CA. Non-diabetic male Sprague–Dawley rats underwent ventricular fibrillation to induce CA, or sham surgery. Rats received 10 mg/kg of empagliflozin or vehicle at 10 min after return of spontaneous circulation by intraperitoneal injection. Cardiac function was assessed by echocardiography, histological analysis, molecular markers of myocardial injury, oxidative stress, mitochondrial ultrastructural integrity and metabolism. We found that empagliflozin did not influence heart rate and blood pressure, but left ventricular function and survival time were significantly higher in the empagliflozin treated group compared to the group treated with vehicle. Empagliflozin also reduced myocardial fibrosis, serum cardiac troponin I levels and myocardial oxidative stress after CA. Moreover, empagliflozin maintained the structural integrity of myocardial mitochondria and increased mitochondrial activity after CA. In addition, empagliflozin increased circulating and myocardial ketone levels as well as heart β-hydroxy butyrate dehydrogenase 1 protein expression. Together, these metabolic changes were associated with an increase in cardiac energy metabolism. Therefore, empagliflozin favorably affected cardiac function in non-diabetic rats with acute myocardial dysfunction after CA, associated with reducing glucose levels and increasing ketone body oxidized metabolism. Our data suggest that empagliflozin might benefit patients with myocardial dysfunction after CA. Frontiers Media S.A. 2021-10-12 /pmc/articles/PMC8546214/ /pubmed/34712142 http://dx.doi.org/10.3389/fphar.2021.758080 Text en Copyright © 2021 Tan, Yu, Liang, Liu, Song, Ge, Fang, Yu, Huang, Jiang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tan, Yunke
Yu, Kai
Liang, Lian
Liu, Yuanshan
Song, Fengqing
Ge, Qiulin
Fang, Xiangshao
Yu, Tao
Huang, Zitong
Jiang, Longyuan
Wang, Peng
Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
title Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
title_full Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
title_fullStr Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
title_full_unstemmed Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
title_short Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
title_sort sodium–glucose co-transporter 2 inhibition with empagliflozin improves cardiac function after cardiac arrest in rats by enhancing mitochondrial energy metabolism
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546214/
https://www.ncbi.nlm.nih.gov/pubmed/34712142
http://dx.doi.org/10.3389/fphar.2021.758080
work_keys_str_mv AT tanyunke sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT yukai sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT lianglian sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT liuyuanshan sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT songfengqing sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT geqiulin sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT fangxiangshao sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT yutao sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT huangzitong sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT jianglongyuan sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism
AT wangpeng sodiumglucosecotransporter2inhibitionwithempagliflozinimprovescardiacfunctionaftercardiacarrestinratsbyenhancingmitochondrialenergymetabolism